drugset / Trial / NCT02238444

Warfarin Prevents Portal Vein Thrombosis in Liver Cirrhotic Patients With Hypersplenism After Laparoscopic Splenectomy

NCT02238444

Phase 4 Unknown 60 enrolled Yangzhou University
RandomizedParallel-groupOpen-labelPrevention

Summary

The purpose of this study is to determine whether Warfarin Anticoagulation are effective and safe in Prevention of Portal Vein Thrombosis in Liver Cirrhotic Patients with Hypersplenism after Laparoscopic Splenectomy.

Timeline

Start
2014-09-01
Primary completion
2019-09-30
Completion
2019-09-30

Drugs

EvaluationDrugModalityDoseRoute
Comparator Aspirin Small molecule 100 mg Oral
Subject Warfarin Small molecule 2.5 mg Oral
Background Dipyridamole Other / unclassified 25 mg Oral
Background Nadroparin Calcium Other / unclassified 4100 iu Subcutaneous